-
EP3814511
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3814511
| EP3814511 - FORMULATIONS FOR SIMIAN ADENOVIRAL VECTORS HAVING ENHANCED STABILITY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 26.07.2024 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 03.04.2021 | ||
| Former | The international publication has been made Status updated on 03.01.2020 | ||
| Former | unknown Status updated on 11.09.2019 | Most recent event Tooltip | 17.10.2024 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states GlaxoSmithKline Biologicals SA Rue de l'Institut, 89 1330 Rixensart / BE | [2021/42] |
| Former [2021/18] | For all designated states GlaxoSmithKline Biologicals S.A. Rue de l'Institut, 89 1330 Rixensart / BE | Inventor(s) | 01 /
MATHOT, Frédéric rue de l'institut 89 1330 Rixensart / BE | 02 /
VASSELLE, Mathieu rue de l'institut 89 1330 Rixensart / BE | [2021/18] | Representative(s) | Furstoss, Olivia Aline GSK W23-F3 20, avenue Fleming 1300 Wavre / BE | [N/P] |
| Former [2021/18] | Furstoss, Olivia Aline GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex, TW8 9GS / GB | Application number, filing date | 19762474.5 | 25.06.2019 | [2021/18] | WO2019IB55347 | Priority number, date | EP20180179977 | 26.06.2018 Original published format: EP 18179977 | [2021/18] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020003126 | Date: | 02.01.2020 | Language: | EN | [2020/01] | Type: | A1 Application with search report | No.: | EP3814511 | Date: | 05.05.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.01.2020 takes the place of the publication of the European patent application. | [2021/18] | Search report(s) | International search report - published on: | EP | 02.01.2020 | Classification | IPC: | C12N15/86 | [2021/18] | CPC: |
C12N15/86 (EP,US);
A61K47/26 (US);
C07K14/765 (US);
A61K35/00 (EP);
C12N2710/10043 (US);
C12N2710/10343 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/18] | Title | German: | FORMULIERUNGEN FÜR AFFEN-ADENOVIRUSVEKTOREN MIT VERBESSERTER STABILITÄT | [2021/18] | English: | FORMULATIONS FOR SIMIAN ADENOVIRAL VECTORS HAVING ENHANCED STABILITY | [2021/18] | French: | FORMULATIONS POUR VECTEURS ADÉNOVIRAUX SIMIENS AYANT UNE STABILITÉ AMÉLIORÉE | [2021/18] | Entry into regional phase | 14.01.2021 | National basic fee paid | 14.01.2021 | Designation fee(s) paid | 14.01.2021 | Examination fee paid | Examination procedure | 14.01.2021 | Examination requested [2021/18] | 14.01.2021 | Date on which the examining division has become responsible | 10.08.2021 | Amendment by applicant (claims and/or description) | 29.07.2024 | Despatch of a communication from the examining division (Time limit: M02) | 16.10.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | Fees paid | Renewal fee | 23.06.2021 | Renewal fee patent year 03 | 21.06.2022 | Renewal fee patent year 04 | 20.06.2023 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.06.2024 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2011103114 (HEMEMICS BIOTECHNOLOGIES INC [US], et al); | [AD]WO2017013169 (GLAXOSMITHKLINE BIOLOGICALS SA [BE]) | by applicant | WO03000283 | WO2005071093 | WO2010086189 | WO2013052799 | WO2013052811 | WO2013052832 | WO2016198621 | WO2016198599 | WO2017013169 | WO2019008111 |